Integrating α-Synuclein Seeding Activity (SAA) into routine practice: insights from the multicenter ALZAN Cohort

This study demonstrates that the alpha-synuclein seed amplification assay (SAA) exhibits high diagnostic accuracy for Lewy body dementia and reveals significant alpha-synuclein co-pathology in Alzheimer's disease, highlighting the necessity of integrating SAA into routine clinical practice to overcome the limitations of standard fluid biomarkers in detecting synuclein pathology.

The Gist

The Big Picture: The "Double Trouble" of Brain Diseases

Imagine your brain is a busy city. In Alzheimer's disease (AD), the city gets clogged with two specific types of trash: Amyloid plaques (like sticky gum on the sidewalks) and Tau tangles (like twisted wires in the power grid).

In Lewy Body Dementia (LBD), the city is clogged with a different kind of trash called Alpha-Synuclein (let's call it "Synuclein Sludge"). This sludge causes the city's traffic lights to flicker, leading to confusion, hallucinations, and movement problems.

The Problem: In the real world, these cities often get clogged with both types of trash at the same time. A patient might have Alzheimer's plus some Synuclein Sludge. Until now, doctors had a hard time seeing the "Sludge" in living patients. They could easily spot the gum and the wires, but the Sludge was invisible unless they looked at the brain after the patient had passed away.

The New Tool: The "Seed Detector"

This study introduces a new, super-sensitive tool called $\alpha$-SAA (Alpha-Synuclein Seed Amplification Assay).

Think of this tool like a high-tech "snowball detector."

• If there is even a tiny, invisible "seed" of Synuclein Sludge in a patient's spinal fluid, this machine takes that seed and helps it grow into a giant snowball in a test tube.
• Once the snowball gets big enough, it glows, telling the doctor: "Yes! There is Synuclein Sludge here!"

What the Researchers Did

The team in France (the ALZAN cohort) tested this "Snowball Detector" on 398 patients visiting memory clinics. They took spinal fluid and blood samples from people with different types of memory loss and ran the test.

The Key Findings (The "Aha!" Moments)

1. It's a Superhero for Lewy Body Dementia

• The Result: When the test was used on patients who actually had Lewy Body Dementia, it was 95% accurate. It almost never missed the Sludge.
• The Analogy: Imagine a metal detector at an airport. If a passenger is carrying a weapon (LBD), this detector beeps 95 times out of 100. It's incredibly reliable for catching this specific disease.

2. It Reveals "Hidden" Trouble in Alzheimer's

• The Result: About 16% of patients diagnosed with Alzheimer's actually had Synuclein Sludge too.
• The Analogy: You think you're just dealing with sticky gum (Alzheimer's), but this test reveals that there's also a hidden layer of Sludge underneath. This "Double Trouble" group (Alzheimer's + Sludge) seemed to have slightly more severe brain changes (lower amyloid ratios) than those with just Alzheimer's.

3. The "Snowball" Grows Faster in LBD

• The Result: In patients with Lewy Body Dementia, the "snowball" (the signal) grew faster and was stronger than in Alzheimer's patients who had some Sludge.
• The Analogy: If you drop a seed in a pot of water, in LBD patients, it explodes into a snowball in 30 minutes. In Alzheimer's patients with co-pathology, it takes 40 minutes. This helps doctors tell the two conditions apart, even when they look similar.

4. Blood Tests Missed the Sludge

• The Result: The researchers checked blood samples for various markers, but none of the blood tests could tell the difference between patients with just Alzheimer's and those with Alzheimer's + Sludge.
• The Analogy: Trying to find the Synuclein Sludge in blood is like trying to find a specific type of fish in the ocean by looking at the water's surface. You can see the waves (other markers), but you can't see the fish. You need to dive deep (spinal fluid) to find it.

Why This Matters for You

1. Better Diagnosis:
Right now, diagnosing Lewy Body Dementia is hard because its symptoms (hallucinations, shaking) can look like Parkinson's or Alzheimer's. This test acts like a truth serum for the brain, confirming if the "Sludge" is present. This helps doctors prescribe the right medication and avoid treatments that might make things worse.

2. Understanding the "Double Trouble":
Finding out that 1 in 6 Alzheimer's patients also has this Sludge is huge. It suggests that some Alzheimer's patients might be declining faster or have different symptoms because of this hidden second disease.

3. The Future of Treatment:
If we can identify these "Double Trouble" patients early, scientists can design better clinical trials. Instead of testing a drug on everyone with memory loss, they can test it specifically on the group with the Sludge. This is the first step toward precision medicine—treating the specific cause of your specific brain problem.

The Bottom Line

This study shows that we finally have a way to "see the invisible" in living patients. By using this new "Seed Detector" on spinal fluid, doctors can:

• Catch Lewy Body Dementia with high accuracy.
• Find hidden "co-infections" of brain diseases in Alzheimer's patients.
• Move away from guessing and start treating based on exactly what is clogging the brain's city streets.

Note: This test currently requires a spinal tap (lumbar puncture), which is a bit invasive, but it is much more accurate than guessing based on symptoms alone.

Technical Summary

1. Problem Statement

Neurodegenerative diseases, particularly Alzheimer's Disease (AD) and Lewy Body Dementia (LBD), are characterized by the accumulation of misfolded proteins. A significant diagnostic challenge is protein co-pathology, where multiple pathologies (e.g., amyloid-beta, tau, and α-synuclein) coexist in the same brain.

• Diagnostic Gap: While post-mortem analysis is the gold standard for detecting α-synuclein aggregates, in vivo diagnosis of LBD and α-synuclein co-pathology in AD patients relies heavily on clinical features and imaging, which lack specificity.
• Limitations of Current Biomarkers: Routine cerebrospinal fluid (CSF) and emerging blood biomarkers (e.g., p-tau, Aβ42/40) are excellent for detecting AD pathology but fail to capture α-synuclein pathology.
• Objective: The study aims to evaluate the feasibility and diagnostic performance of the α-synuclein Seed Amplification Assay (αSAA) in a real-world, routine clinical setting and to characterize the impact of α-synuclein co-pathology on cognitive and biological profiles in a large cohort of cognitively impaired patients.

2. Methodology

Study Design & Population:

• Cohort: The prospective, multicenter ALZAN cohort (NCT05427448) recruited 398 patients from memory clinics in Montpellier, Nîmes, and Perpignan, France (Nov 2022 – July 2024).
• Diagnosis: Participants were clinically diagnosed by two senior neurologists into four groups:
  • Alzheimer's Disease (AD): $n=203$
  • Lewy Body Dementia (LBD): $n=20$
  • Frontotemporal Dementia (FTD): $n=30$
  • Other (including subjective cognitive impairment): $n=138$
• Data Collection: All participants underwent lumbar puncture (CSF) and blood sampling. Cognitive function was assessed via the Mini-Mental State Examination (MMSE).

Biomarker Analysis:

• CSF: Measured Aβ40, Aβ42, Total Tau, and p-tau181 using the Lumipulse G1200® system. The Aβ42/40 ratio was used to define amyloid pathology.
• Plasma: Measured p-tau217, p-tau181, Aβ42/40, GFAP, and NfL using Elecsys® assays (Roche) and Lumipulse G1200®.
• αSAA Protocol:
  • Technique: Real-time Quaking-Induced Conversion (RT-QuIC).
  • Conditions: Incubation at 42°C with intermittent shaking; Thioflavin T fluorescence monitored every 45 minutes for 168–225 hours.
  • Positivity Criteria: A sample was $\alpha$SAA+ if at least one of four replicates exceeded a fluorescence threshold (50% of the mean ratio between aggregation and baseline of the positive control).
  • Quantitative Parameters: Lag phase (time to doubling), Maximum Fluorescence (Fluomax), Area under the curve, and number of positive replicates.

Statistical Analysis:

• Comparisons used $\chi^2$ tests, Student's $t$-tests, and ANOVA with Tukey's HSD post-hoc tests.
• ROC curves were generated to assess diagnostic performance.

3. Key Contributions

1. Real-World Validation: This is one of the first large-scale studies to implement αSAA in a routine clinical practice setting (unselected patients with pre-analytical variations), rather than a highly controlled research cohort.
2. Diagnostic Performance: It provides robust sensitivity and specificity data for distinguishing LBD from other dementias using αSAA in a clinical workflow.
3. Co-Pathology Characterization: It quantifies the prevalence of α-synuclein co-pathology in a clinical AD cohort and investigates whether this co-pathology alters standard AD biomarker profiles or cognitive scores.
4. Kinetic Differentiation: It explores whether kinetic parameters of the RT-QuIC assay (Lag phase, Fluomax) can differentiate between pure LBD and AD with co-pathology.

4. Key Results

Diagnostic Performance of αSAA:

• LBD Detection: The assay showed 95.0% sensitivity (19/20 patients) and 93.5% specificity (in non-AD/non-LBD controls) for LBD. The Negative Predictive Value (NPV) was 99.4%.
• AD Co-Pathology: 15.8% of clinically diagnosed AD patients (32/203) tested $\alpha$SAA+, indicating significant α-synuclein co-pathology.
• Other Groups: 0% of FTD patients and 7.9% of "Other" patients were $\alpha$SAA+.

Kinetic Parameters:

• LBD vs. AD: LBD patients exhibited a significantly shorter Lag phase ($p=0.0254$) and a higher number of positive replicates ($p=0.0018$) compared to AD patients.
• Overlap: Despite these differences, Fluomax and Area under the curve showed significant overlap between groups, limiting their standalone utility for differentiation.

Impact of $\alpha$SAA Status on Biomarkers and Cognition:

• Whole Cohort: $\alpha$SAA+ patients were older, had lower MMSE scores, lower CSF Aβ42/40 ratios, and higher plasma GFAP compared to $\alpha$SAA- patients.
• Within AD Subgroup (Crucial Finding):
  • Cognition: No significant difference in MMSE scores between AD+$\alpha$SAA+ and AD+$\alpha$SAA- ($p=0.27$).
  • Biomarkers: No significant differences in plasma p-tau217, NfL, or GFAP.
  • Amyloid Burden: The CSF Aβ42/40 ratio was significantly lower in AD+$\alpha$SAA+ patients ($4.6\%$ vs $5.2\%; p=0.0096$), suggesting a higher amyloid burden in those with co-pathology.
  • Conclusion: The presence of α-synuclein co-pathology in AD does not appear to drastically alter standard blood/CSF tau/amyloid profiles or cross-sectional cognitive scores, except for a trend toward higher amyloid load.

5. Significance and Implications

• Clinical Utility: αSAA is a highly accurate tool for detecting LBD in routine practice, offering a biological confirmation that clinical criteria often miss.
• Precision Medicine: The detection of α-synuclein co-pathology in AD patients (approx. 1 in 6) highlights the heterogeneity of AD. Identifying these subgroups is critical for:
  • Clinical Management: Anticipating specific symptom profiles (e.g., motor or visual hallucinations).
  • Therapeutic Trials: Optimizing participant selection for trials targeting specific pathologies (e.g., anti-amyloid vs. anti-synuclein therapies).
• Limitations of Current Biomarkers: The study underscores that standard AD biomarkers (plasma p-tau, NfL) are insufficient to detect α-synuclein pathology, reinforcing the need to integrate αSAA into the diagnostic workup for neurodegenerative diseases.
• Future Directions: While cross-sectional data showed limited impact on cognition, the authors suggest longitudinal studies are needed to determine if α-synuclein co-pathology drives faster cognitive decline.

Conclusion: The ALZAN cohort study validates the integration of αSAA into routine memory clinics. It confirms high diagnostic accuracy for LBD and reveals a substantial burden of α-synuclein co-pathology in AD, which is biologically distinct (higher amyloid burden) but not immediately distinguishable by current standard blood or CSF tau/amyloid markers alone.